Home / Resource Library / 7-YEAR UPDATE ON A PHASE 2 TRIAL OF FIXED-DURATION OBINUTUZUMAB, IBRUTINIB, AND VENETOCLAX FOR CLL7-YEAR UPDATE ON A PHASE 2 TRIAL OF FIXED-DURATION OBINUTUZUMAB, IBRUTINIB, AND VENETOCLAX FOR CLL EHA 2024